Innova Biosciences Awarded EU Grant to Develop Cancer Biomarker Discovery Platform
News Feb 18, 2009
Innova Biosciences Ltd has been awarded €455,000 of a €3,000,000 European grant. Through the PROACTIVE consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University, and Integromics S.L., a high throughput plasma screening platform will be developed for the discovery of biomarkers of early stage cancer.
Innova Biosciences has had enormous success with its range of Lightning-Link™ bioconjugation products, which provide a simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide.
Innova Biosciences’ participation in the PROACTIVE consortium to develop immunodiagnostics reagents will help cement the company’s position as a world leader in bioconjugation technology.
Commenting on the EU grant Dr Nick Gee, CEO of Innova Biosciences said “We are delighted to be granted such a prestigious award which recognizes Innova’s proprietary knowledge and expertise. Participating in the development of a new immunodiagnostic platform that will facilitate early stage cancer detection is an exciting application of our technology, which will directly benefit human health.”
Researchers say they have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a lower risk of diabetes, obesity, heart failure, and even death. The researchers say their finding could provide the basis for drug therapies that could mimic the workings of this gene mutation.
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019